iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical
Retrieved on:
Thursday, December 31, 2020
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), iCo Therapeutics, Inc. ("iCo") and Skymount Medical, Inc. ("Skymount") announced today that they have entered into a non-binding Memorandum of Understanding to develop iCo-019, iCo's oral Amphotericin B formulation.
Key Points:
- Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), iCo Therapeutics, Inc. ("iCo") and Skymount Medical, Inc. ("Skymount") announced today that they have entered into a non-binding Memorandum of Understanding to develop iCo-019, iCo's oral Amphotericin B formulation.
- "The Skymount Medical team is honored to be collaborating with iCo to improve global public health for COVID and other indications.
- iCo and Skymount expect to begin joint development of iCo-019 for COVID-19-related indications in Q1, 2021.
- iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases.